HBL Hadasit Bio Hldgs.

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2019, HBL Hadasit Bio Hldgs. has already paid €0.14 in dividends. The last payout was in February 2019.

Financials

In the last quarter, HBL Hadasit Bio Hldgs. had revenue of €0 and net profit of -€116.68k

(EUR)	June 2025	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-116.68k	-
EBITDA	0	-

Fundamentals

Metric	Value
Market capitalization	€1.18m
Number of shares	11.09m
52-week high/low	€0.12 - €0.11
Dividends	No
Beta	0.49
P/E ratio	-1.22
PEG ratio	-0.01
P/B ratio	2.60
P/S ratio	0.00

Company profile

Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.